Please login to the form below

Not currently logged in
Email:
Password:

NICE backs Amicus Therapeutics’ Galafold

Recommends oral alternative for treating Fabry disease
NICE

The UK's NICE has recommended the use of Galafold (migalastat) on the NHS for the treatment of Fabry disease in draft Highly Specialised Technologies guidance.

The committee gave Amicus Therapeutics' genetic disorder treatment the provisional green light, bringing UK patients one step closer to an orally administered alternative to the standard fortnightly injections.

Despite initial uncertainty over its clinical effectiveness, the cost-effectiveness watchdog concluded that Galafold provides enough similar benefits to current enzyme replacement therapies (ERT), such as Sanofi's Fabrazyme (agalsidase beta) and Shire's Replagal (agalsidase alfa).

The regulator has agreed a confidential discount for the therapy with Amicus, creating a patient access scheme to reduce pricing from its annual treatment cost of £210,000 per patient in line with current ERT programmes.

Fabry disease affects an estimated 855 people in England, of whom around 140 would be eligible for treatment with Galafold.

An incurable inherited genetic disorder, Fabry disease is caused by a faulty enzyme responsible for breaking down fatty substances in the body's cells. Build up of lipids in blood vessel walls decreases blood flow to tissues and so often results in irreversible organ damage, progressive kidney and heart disease and increased risk of stroke.

Article by
Rebecca Clifford

28th October 2016

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics